Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.53 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3492958 | 0.90 | ALDH1A1 (0.53) | ALDH1A1KMT2AMEN1KDM4EMAPT | |
| SCHEMBL490309 | 0.87 | ALOX5 (0.66) | ALDH1A1KMT2AGAACYP4F2CYP4A11 | |
| SCHEMBL28222447 | 0.85 | KMT2A (0.55) | ALDH1A1KMT2AMEN1MAPTGAA | |
| SCHEMBL7431362 | 0.85 | MAPT (0.63) | ALDH1A1KMT2AMEN1MAPTGAA | |
| SCHEMBL3457181 | 0.83 | ALDH1A1 (0.70) | ALDH1A1KMT2AMEN1KDM4EMAPT | |
| SCHEMBL491276 | 0.83 | CYP4F2 (0.59) | KMT2AMEN1KDM4ECYP4F2CYP4A11 | |
| SCHEMBL12812251 | 0.82 | KMT2A (0.51) | ALDH1A1KMT2AMEN1KDM4EMAPT | |
| SCHEMBL8912630 | 0.81 | CYP4F2 (0.58) | ALDH1A1KMT2ACYP4F2CYP4A11 | |
| SCHEMBL9832305 | 0.81 | ALDH1A1 (0.56) | ALDH1A1KMT2AMEN1KDM4EGAA | |
| SCHEMBL11212268 | 0.81 | ALOX5 (0.55) | ALDH1A1KMT2ACYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2994460-B1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | UNIV INDIANA RES & TECH CORP (US) | 2024-12-04 | — | — | EP | disclosed |
| US-10738024-B2 | Compounds for treatment of angiogenesis-mediated diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-08-11 | — | — | US | disclosed |
| US-10238627-B2 | Compounds for treatment of angiogenesis-mediated diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180177758-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2018-06-28 | — | — | US | disclosed |
| EP-2994460-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | Indiana University Research and Technology Corporation (US) | 2016-03-16 | — | — | EP | disclosed |
| US-20160060241-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-03-03 | — | — | US | disclosed |
| WO-2014182695-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2014-11-13 | — | — | WO | disclosed |
| US-8268293-B2 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | MERCK PATENT GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| CN-101163659-B | Antioxidants | MERCK PATENT GMBH | 2012-09-05 | — | — | CN | disclosed |
| US-8106233-B2 | Applying di-2-ethylhexyl 4-hydroxy-3,5-dimethoxy-benzylmalonate; protective action against UV rays, oxidative stress on body cells, counters skin ageing | MERCK PATENT GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-5414108-A | From a Meldrum's acid derivative | BIOGAL GYOGYSZERGRAR (HU) | 1995-05-09 | — | — | US | disclosed |
| US-5350872-A | Decyclization and decarboxylation of a 1,3-dioxane-4,6-dione | BIOGAL GYOGYSZERGRAR (HU) | 1994-09-27 | — | — | US | disclosed |
| EP-0578850-A1 | Process for the preparation of carboxylic acids and derivatives of them | BIOGAL GYOGYSZERGYAR (HU) | 1994-01-19 | — | — | EP | disclosed |
| US-4523015-A | Process and nitroaminopyrimidone intermediates for histamine H2 -antagonists | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-06-11 | — | — | US | disclosed |
| EP-0004793-B1 | 2-NITRO AMINOPYRIMIDONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE TO PREPARE 2-AMINOPYRIMIDONE DERIVATIVES WHICH HAVE HISTAMINE H2-ANTAGONIST ACTIVITY | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1981-12-30 | — | — | EP | disclosed |
| US-4227000-A | Intermediates in the process for making histamine antagonists | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-10-07 | — | — | US | disclosed |
| US-4218452-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-08-19 | — | — | US | disclosed |
| EP-0004793-A2 | 2-nitro aminopyrimidone derivatives, a process for their preparation and their use to prepare 2-aminopyrimidone derivatives which have histamine H2-antagonist activity | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-10-17 | — | — | EP | disclosed |
| US-4159329-A | BLOCKING AGENTS, ANTAGONISTS, ANTIHISTAMINES | SMITHKLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-06-26 | — | — | US | disclosed |
| US-4145546-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738024-B2 | Compounds for treatment of angiogenesis-mediated diseases | KDR, TEK, VEGFA | ALDH1A1 1077/4885KMT2A 4465/4885MEN1 2818/4885 |
| US-20180177758-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | KDR, TEK, VEGFA | ALDH1A1 1077/4885KMT2A 4465/4885MEN1 2818/4885 |
| US-20160060241-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | KDR, TEK, VEGFA | ALDH1A1 1077/4885KMT2A 4465/4885MEN1 2818/4885 |
| US-10238627-B2 | Compounds for treatment of angiogenesis-mediated diseases | KDR, TEK, VEGFA | ALDH1A1 1077/4885KMT2A 4465/4885MEN1 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.